AstraZeneca PLC Fourth quarter and full year results 2012

Thursday, 31 January 2013

Pascal Soriot, Chief Executive Officer, commenting on the results, said:

"Our performance in 2012 reflects a period of significant patent expiry and tough market conditions globally. Despite the challenges we face, I am excited about AstraZeneca’s fundamental strengths which will be key in returning the Company to growth and achieving scientific leadership while maintaining our reputation for strong financial discipline. It is my firm belief that we have the brands, science, pipeline and people to create distinctive, long-term value for patients and shareholders. Our new leadership team and I look forward to elaborating on these themes at our Capital Markets Day in March."

FOURTH QUARTER AND FULL YEAR RESULTS 2012

Announced on Thursday 31 January 2013

Downloads

Webcast

View the webcast